Regarding secondary endpoints , in the ITT population colesevelam-treated patients had a significant reduction of liquid stools/day at week 4 ( median 5.0 to 2.0 ; P = 0.01 ) , while patients treated with placebo had no significant reduction ( median 4.0 to 3.0 ; P = 0.42 ) .